HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies

Ji Wang1, Pei Tong1, Lu Lu2,3, Leilei Zhou1, Liling Xu1, Shibo Jiang2,3, Ying-hua Chen1

1 School of Life Sciences, Tsinghua University, Beijing, China, 2 New York Blood Center, Lindsley F. Kimball Research Institute, New York, New York, United States of America, 3 Key Laboratory of Medical Molecular Virology of Ministry of Education/Ministry of Health and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China

Abstract

The membrane-proximal external region (MPER) of the HIV-1 gp41 consists of epitopes for the broadly cross-neutralizing monoclonal antibodies 2F5 and 4E10. However, antibodies containing the linear sequence of these epitopes are unable to elicit potent and broad neutralizing antibody responses in vaccinated hosts, possibly because of inappropriate conformation of these epitopes. Here we designed a recombinant antigen, designated NCM, which comprises the N- and C-terminal heptad repeats that can form a six-helix bundle (6HB) core and the MPER domain of gp41. Two mutations (T569A and I675V) previously reported to expose the neutralization epitopes were introduced into NCM to generate mutants named NCM(TA), NCM(IV), and NCM(TAIV). Our results showed that NCM and its mutants could react with antibodies specific for 6HB and MPER of gp41, suggesting that these antibodies are in the form of a trimer of heterodimer (i.e., 6HB) with three exposed MPER tails. Antibodies with double mutations, NCM(TAIV), elicited much stronger antibody response in rabbits than immunogens with single mutation, NCM(TA) and NCM(IV), or no mutation, NCM. The purified MPER-specific antibodies induced by NCM(TAIV) exhibited broad neutralizing activity, while the purified 6HB-specific antibodies showed no detectable neutralizing activity. Our recombinant antigen design supported by an investigation of its underlying molecular mechanisms provides a strong scientific platform for the discovery of a gp41 MPER-based AIDS vaccine.

Introduction

As the acquired immunodeficiency syndrome (AIDS) pandemic continues to expand globally, the search for a preventive vaccine is an absolute priority in combating its causative agent, human immunodeficiency virus type 1 (HIV-1). Stimulating the humoral arms of the host immune response and designing immunogens capable of eliciting broadly neutralizing antibodies (BNAbs) is a paramount goal for AIDS vaccine development [1]. However, the ability of HIV-1 to evade host immune defenses, along with substantial genetic variation, has posed major stumbling blocks to thwart this effort [2].

Clinical studies indicate that the antisera of some HIV-1-infected patients exhibit broad and potent neutralizing activity [3,4]. Nevertheless, only a handful of BNAbs have been identified to date. Three of those, monoclonal antibodies (mAbs) 2F5, 4E10 and Z13, target the adjacent linear epitopes located in the membrane-proximal external region (MPER) of gp41 [5,6], which plays a crucial role in membrane fusion and viral entry. The gp41 ectodomain contains the N- and C-terminal heptad repeats (NHR and CHR), which can interact with each other to form a six-helix bundle (6HB, also known as a trimer of heterodimers), a fusion core conformation of gp41 (Fig. 1A). The mAb 2F5 recognizes a core epitope of six amino acids ELDKWA (aa 662–667) in the MPER [5]. The core binding motif, DKW, is in an extended β-turn conformation in complex with 2F5 antibody as shown by crystallographic study [7]. The 4E10 epitope comprises the linear sequence NWFNIT (aa 671–676) and adopts a helical conformation [9]. The residue F673 swings 180° from membrane interior to the antibody binding pocket [10]. Before the recent identification of BNAbs PG9, PG16, VRC01 and VRC02 [10,11,12], 2F5 had been the most potent neutralizing antibody, whereas 4E10 was able to neutralize the broadest range of different viral isolates [13,14]. The relatively conserved and linear property of these neutralizing epitopes makes MPER one of the most attractive targets for development of an HIV-1 vaccine.

Unfortunately, in contrast to the loop region of gp41, the MPER is weakly immunogenic [15]. A number of immunization studies demonstrated that the MPER-containing recombinant proteins, proteins expressed on Virus-Like Particles (VLPs) and
chimeric proteins all failed to elicit MPER-specific neutralizing antibodies [16,17,18]. Thus, designing immunogens that produce high titers of MPER-specific antibodies is the prerequisite for an MPER-based vaccine. Blish et al. have shown that introduction of two mutations (T569A and I675V) into gp41 results in significantly enhanced exposure of the conserved neutralization epitopes in MPER and renders the HIV-1 mutants 360- and 180-fold more susceptible to 2F5 and 4E10, respectively [19].
Therefore, we hypothesized that introducing these two mutations into an MPER-based HIV-1 vaccine candidate might increase its immunogenicity to elicit stronger MPER-specific antibodies with broad neutralizing activity. In the present study, we constructed and expressed a recombinant immunogen consisting of the N- and C-terminal heptad repeats that can form a six-helix bundle (6HB) and the MPER region of gp41. Two mutations (T569A and I675V) previously reported to expose the neutralization epitopes were introduced into NCM to generate mutants named NCM(TA), NCM(IV) and NCM(TAIV). As expected, relatively high titers of the MPER-specific antibodies were induced by NCM(TAIV). These antibodies exhibited broad and potent neutralizing activity.

Materials and Methods

Peptides, cells and viruses

All peptides, including MPER (aa 659–683), MPER(IV) (MPER peptide with I675V mutation), M1 (aa 645–663), M2 (aa 638–672), M3 (aa 662–676) and M4 (aa 671–683), were synthesized by SBS Genetech, Beijing, China, with purity >90%.

3T3 cells stably transduced with MLV MX-CD4 and MX-CXCR4 vectors (3T3.T4.CXCR4) were cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). CHO cells stably transfected with either the HIV-1 HXB2 Env expressing vector pEE14 (CHO-WT) or control pEE14 vector (CHO-EE) were cultured in modified Eagle medium (GMEM) containing 400 μM Methionine sulfoximine (Sigma, St. Louis, MO).

MT-2 and TZM-bl cells; plasmids, including pNL4-3.LucR E2 and pMD2.G were used as a target for HIV-1 infection. The cells were exposed to Env-expressing viruses such as HIV-1 HXB2, HIV-1 IIIB, HIV-1 Bal, and primary HIV-1 isolates, were obtained from the NIH AIDS Research and Reference Reagent Program. GFP-transduced human osteosarcoma cells (Ghost) target cells which express CD4 and both coreceptors CCR5 and CXCR4 were kindly provided by Dr. Linqi Zhang at Tsinghua University.

Protein expression and purification

NCM is composed of the NHR (aa 546–581) followed by an 8 amino acids linker (GGGKLGGG), CHR (aa 628–658) and MPER (aa 659–683). The cDNA was amplified from pcDNA3.1- gp160 (HXB2) plasmid and cloned into pGEX-6p-1 vector (GE Healthcare, Sweden). Three mutations were constructed by a standard point mutation method by PCR. The plasmids were transformed into E. coli strain Rosetta. The proteins were induced at 16°C with 1 mM IPTG for 12 hours. Purification of the proteins followed a standard procedure with glutathione Sepharose 4B Fast flow beads (GE Healthcare, Sweden). The GST-fusion proteins on beads were cut by PreScission protease (GE Healthcare, Sweden) at 4°C overnight in PPase buffer (150 mM NaCl, 100 mM Tris, 1 mM EDTA, 1 mM DDT). The beads were washed with 1 mM glutathione in PBS to remove GST (NCM bound tightly to beads). The NCMs were collected by washing beads with 6 M guanidine. All proteins were purified to homogeneity by Vydac C4 Reversed-Phase Columns (Grace, MA), lyophilized and stored at −20°C. NCMs were dissolved by PBS buffer with 0.1% triton X-100 for hydrophobic character of MPER. Expression and purification of six-helix bundle (6HB) protein composed of NHR and CHR of gp41, N36/L6/C34, was described previously [20]. Protein concentrations were quantified with bicinchoninic acid (BCA) assay.

Chemical cross-linking and Western blot analysis

Cross-linking study was performed as described by Mische et al [21]. Briefly, NCMs were treated with 0, 0.1, 0.4 and 4 mM glutaraldehyde (GA), respectively, for 1.5 h at room temperature and were separated by SDS-PAGE. The protein bands in the gels were transferred into a PVDF membrane (Millipore) and analyzed with Western blot using the mAb NC-1 [22] as the primary antibody.

Table 1. The immunogenicity of NCMs after the third immunization.

| Group | Immunogen | Rabbit | Titers of antibodies specific for |
|-------|-----------|--------|----------------------------------|
|       |           |        | No                              |
|       |           |        | Immunogen        | MPER peptide | MPER (IV) peptide |
| I     | NCM       | 1      | 1:4×10⁴ | <1:400 | <1:400 |
|       |           | 2      | 1:1×10⁵ | 1:1600 | 1:800 |
|       |           | 3      | 1:1×10⁵ | <1:400 | <1:400 |
| Geometric mean titer | 1:1.6×10⁵ | 1:635 | 1:504 |
| II    | NCM(IV)   | 4      | 1:1×10⁵ | 1:800 | 1:800 |
|       |           | 5      | 1:4×10⁵ | 1:3200 | 1:3200 |
|       |           | 6      | 1:4×10⁵ | 1:400 | 1:400 |
| Geometric mean titer | 1:2.5×10⁵ | 1:1008 | 1:1008 |
| III   | NCM(TA)   | 7      | 1:1×10⁵ | 1:1600 | 1:800 |
|       |           | 8      | 1:1×10⁵ | <1:400 | <1:400 |
|       |           | 9      | 1:4×10⁵ | 1:3200 | 1:3200 |
| Geometric mean titer | 1:1.6×10⁵ | 1:1270 | 1:1008 |
| IV    | NCM(TAIV) | 10     | 1:4×10⁵ | 1:12800 | 1:12800 |
|       |           | 11     | 1:4×10⁵ | 1:25600 | 1:25600 |
|       |           | 12     | 1:4×10⁵ | 1:25600 | 1:25600 |
| Geometric mean titer | 1:4×10⁵ | 1:20319 | 1:16127 |

Note: “<1:400” was treated as 1:400 when the Geometric mean titer was calculated.
Enzyme-linked immunosorbent assay (ELISA)

The NCMs were coated onto the microtiter plates (0.25 μg/well, pH 9.6, 0.1 M NaHCO₃) at 4°C overnight and blocked by 0.3% gelatin in PBS for 1 h. Then the primary antibodies 2F5, 4E10 (Polymun, Austria) or NC-1 were added and incubated for 1 h. Thereafter, the peroxidase-conjugated anti-human (Sigma, MO) or anti-mouse immunoglobulin antibodies (Dako, Denmark) were added, and 1 h incubation was performed. The freshly prepared substrate solution (10 mg OPD in 10 ml, pH 5.0, 0.1 M citrate buffer, and 18 μl H₂O₂) was then added to each well. The reaction was stopped by 2 M H₂SO₄ 10 minutes later, and the absorbance at 490 nm (A₄₉₀) was read by a Bio-Rad Model 680 (Hercules, CA).

Surface plasmon resonance (SPR) assay

A BIAcore X instrument was used in SPR binding assays. The SPR experiment to investigate the binding of 2F5 to NCMs on membrane was performed as previously described [23]. Briefly, liposomes of a mixture of POPC/Chol/SM (1:1:1) were captured onto sensor chip L1 surface. After washing away the loosely bound liposomes by a NaOH pulse, 45 μl 0.6 μM NCM or mutants were injected. Then the capture levels were measured after a 400 s delay. 0.01% Triton X-100 in buffer, which was crucial for NCM solubility, was confirmed not to cause large baseline changes in this study by buffer-only injections over membrane surface (changed 51±16 RU, 0.5% of capture level of liposomes to chip surface). Injections of 2F5 (50–200 nM, 60 s) or 4E10 (100–300 nM, 96 s) were taken subsequently, followed by uniform dissociation time (600 s). The data were analyzed by BIAevaluation 3.1 in 1:1 binding with drifting baseline model, which had lower χ² values than those of a two-step binding model.

Figure 2. Binding of anti-gp41 mAbs to NCMs. Binding of human mAb 2F5 (A), 4E10 (B) and mouse mAb NC-1 (C) to NCMs, as determined by ELISA.

Figure 3. Binding of antisera to MPER or MPER(IV) peptide. Two-fold serially diluted rabbit sera were added to peptide MPER- (A) or MPER(IV) (B) -coated 96-well plates. Each datum is the average of A₄₉₀ value of three rabbits in the same group.
Rabbit immunization and serological test

Twelve female New Zealand rabbits enrolled for the immunization were randomly allotted to four different groups, three for each group (Table 1). The study of animals was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and Tsinghua University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Tsinghua University (Permit Number: 2010-ChenYH-A2). All efforts were made to minimize suffering. The rabbits were immunized 3 times with 50 mg immunogen at day 0, 14 and 28 by subcutaneous injections. Complete Freund's adjuvant was used for the priming and incomplete Freund's adjuvant for the next two boosts. Pre-immunization blood samples were collected one day before the primary immunization. The terminal bleeding was done on day 35. Sera were stored at \(-20^\circ\text{C}\).

The immunogenicity of NCMs and MPER in the individual immunogens was characterized by indirect ELISA. The synthetic peptide MPER or NCMs were coated onto the microtiter plates (0.25 mg/well). Sera were serially diluted and added into wells. The peroxidase-conjugated anti-rabbit immunoglobulin antibodies (Dako, Denmark) served as secondary antibodies. The OPD substrate was used and quenched by 2 M H2SO4 10 minutes later. Titers of the antigen-specific antibodies were expressed as the highest dilution of serum that reacted with the coating antigens (the average values of A490 nm ≥0.2).

Purification of MPER- and 6HB-specific antibodies from rabbit antisera

Two mg of MPER peptide (aa 659–683) or a recombinant 6HB mimetic, N36(L8)C34 were coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare, Sweden) for purification of MPER- or 6HB-specific antibodies according to the manufacturer’s instruction. Briefly, sera were diluted four times with PBS and passed through the affinity column. The column was washed with 20 ml PBS to remove nonspecific antibodies. The MPER- or 6HB-specific antibodies were eluted with low pH elution buffer (pH 2.5, 0.1 M Glycine). The purified antibodies were then

Table 2. Neutralizing activity of anti-MPER antibodies against Env-mediated syncytium-formation and infection by HIV-1 pseudoviruses, laboratory-adapted and primary strains.

| HIV-1 isolates                      | Subtypes | Coreceptor tropism | IC50 (µg/ml) |
|------------------------------------|----------|--------------------|--------------|
|                                    |          |                    | Anti-6HB IgG | Anti-MPER IgG | 2F5 | 4E10 |
| Env-mediated syncytium-formation   |          |                    | >150         | 8.7±3.8       | 6.7±2.9 | 21.0±12.4 |
| HIV-1 pseudoviruses                |          |                    | >150         | 15.2±3.3      | 1.0±0.1 | 0.6±0.3 |
| HXB2                               | B        | X4                 | >150         | 23.8±6.4      | 1.4±0.2 | 3.9±2.1 |
| JRFL                               | B        | R5                 | >150         | 64.6±16.8     | 13.2±3.7 | 8.3±1.6 |
| Laboratory-adapted HIV-1 strains   |          |                    | >150         | 79.6±2.6      | 16.1±5.1 | 9.2±1.1 |
| IIIB                               | B        | X4                 | >150         | >150          | 27.1±4.3 | 41.8±8.3 |
| Bal                                | B        | R5                 | >150         | >150          | 142.1±27.7 | 10.2±2.9 | 7.5±3.5 |
| Primary HIV-1 isolates             |          |                    | >150         | 140.5±18.9    | 37.5±5.6 | 7.1±1.7 |
| 94UG103                            | A        | X4R5               | >150         | >150          | 172.4±8.2 | 25.1±7.6 |
| 92US567                            | B        | R5                 | >150         | >150          | 98.2±11.5 | 6.3±1.1 | 3.5±0.9 |
| 92TH009                            | A/E      | R5                 | >150         | >150          | 150±6.6  | 10.2±2.9 | 7.5±3.5 |

Rabbit immunization and serological test

Two female New Zealand rabbits enrolled for the immunization were randomly allotted to four different groups, three for each group (Table 1). The study of animals was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and Tsinghua University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Tsinghua University (Permit Number: 2010-ChenYH-A2). All efforts were made to minimize suffering. The rabbits were immunized 3 times with 50 µg immunogen at day 0, 14 and 28 by subcutaneous injections. Complete Freund’s adjuvant was used for the priming and incomplete Freund’s adjuvant for the next two boosts. Pre-immunization blood samples were collected one day before the primary immunization. The terminal bleeding was done on day 35. Sera were stored at \(-20^\circ\text{C}\).

The immunogenicity of NCMs and MPER in the individual immunogens was characterized by indirect ELISA. The synthetic peptide MPER or NCMs were coated onto the microtiter plates (0.25 µg/well). Sera were serially diluted and added into wells. The peroxidase-conjugated anti-rabbit immunoglobulin antibodies (Dako, Denmark) served as secondary antibodies. The OPD substrate was used and quenched by 2 M H2SO4 10 minutes later. Titers of the antigen-specific antibodies were expressed as the highest dilution of serum that reacted with the coating antigens (the average values of A490 nm ≥0.2).

Purification of MPER- and 6HB-specific antibodies from rabbit antisera

Two mg of MPER peptide (aa 659–683) or a recombinant 6HB mimetic, N36(L8)C34 were coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare, Sweden) for purification of MPER- or 6HB-specific antibodies according to the manufacturer’s instruction. Briefly, sera were diluted four times with PBS and passed through the affinity column. The column was washed with 20 ml PBS to remove nonspecific antibodies. The MPER- or 6HB-specific antibodies were eluted with low pH elution buffer (pH 2.5, 0.1 M Glycine). The purified antibodies were then

Figure 4. Inhibitory activity of antibodies on cell-to-cell transmission of HIV-1. Anti-MPER IgGs and ani-6HB IgGs were tested for inhibition of HIV-1 IIIB and Bal transmission from PBMCs to CEMx174 5.25M7 cells. doi:10.1371/journal.pone.0018233.g004
concentrated and transferred to PBS by using a 30 kD ultra centrifugal filter device (Millipore, MA). The antibody concentrations were quantified by measuring absorbance at 280 nm and stored at 4°C until use.

Assay for HIV-1 Env-mediated syncytium-formation

The assay for detecting the HIV-1 Env-mediated syncytium-formation was performed as previously described [24]. Briefly, (3T3.T4.CXCR4) cells (5×10^4) were plated in 48-well plates, followed by an overnight incubation at 37°C and washed with GMEM-S medium. Then, 3×10^4 effector (CHO-WT) cells prestimulated with 6.5 mM sodium butyrate for about 20 h were added in the presence of an antibody at a serial 2-fold dilution. After a co-culture at 37°C for 24 h, the syncytia, defined as giant cells with diameters more than four times larger than those of single cells, were counted under a microscope. The percentage inhibition of syncytium-formation was calculated as previously described [24], and the concentration for 50% inhibition (IC50) was calculated using the CalcuSyn software [25].

HIV-1 neutralization assays

The neutralizing activity of antibodies was first determined using a single-cycle pseudovirus infection assay as previously described [26]. In brief, pseudoviruses were generated by transient transfection of HEK 293T cells with pNL4-3.LucR’E’ and an Env-expressing plasmid pHXB2 or pJRFL. The mixture of a pseudovirus at a concentration yielding 50,000–100,000 relative luminescence units (RLU) and a serial 2-fold dilution of an antibody (final concentration 4.7–150 µg/ml) was added to DMEM medium in wells of 96-well plates to reach a total volume of 100 µl. After incubation at 37°C for 1 h, 100 µl of Ghost cells (1×10^7/ml) were added and cultured at 37°C in 5% CO2 for 48 h. RLU’s were determined with a luciferase kit (Promega, Madison, WI) and luminometer (Ultra 386, Tecan, Durham, NC) following the instructions of the manufacturers.

The neutralizing activity of antibodies on infection by HIV-1 strain IIIB was determined as previously described [27]. Briefly, MT-2 cells (1×10^4/well) were infected with HIV-1 IIIB at 100 TCID50 (50% tissue culture infective dose) in the absence or presence of 2-fold serially diluted antibodies in 200 µl RPMI medium 1640 containing 10% FBS overnight. The supernatants were removed, and fresh medium was added the next day. On the fourth day post-infection, 100 µl of culture supernatants from each well were collected and mixed with equal volumes of 5% Triton X-100 for testing p24 antigen using an in-house ELISA previously described [27].

The neutralizing activity of antibodies on infection by HIV-1 R5 strain Bal and primary isolates was performed as described before [28]. Briefly, 100 µl of TZM-bl cells (1×10^5/ml) were pre-
cultured overnight, followed by addition of a mixture of a virus at 100 TCID₅₀ in the absence or presence of a serially diluted antibody. After co-culture at 37°C for 48 h, the cells were harvested and lysed by the lysis reagent in the luciferase assay kit. The RLUs were determined with luciferase kit and luminometer as described above. The percent of inhibition and the IC₅₀ values were calculated with the CalcuSyn software as described above.

Assessment of inhibition of antibodies on HIV-1 transmission from PBMCs to CEM×174 5.25M7 cells

Inhibitory activity of antibodies on HIV-1 transmission was assessed as previously described [29]. In brief, PHA/IL-2-stimulated PBMCs were infected by HIV-1 IIIB and Bal (a multiplicity of infection of 0.01) for 7 days and washed with culture medium for 3 times to remove free viral particles. Subsequently, 50 μl of HIV-1-infected PBMCs (1×10⁶/ml) were incubated with 50 μl of antibodies at 37°C for 30 min. Then, 100 μl of CEMx174 5.25M7 cells (5×10⁵/ml) were added and co-cultured at 37°C for 72 h. The cells were collected and lysed for analysis of luciferase activity, using a luciferase assay kit (Promega) as described above.

Results

Expression, purification, and characterization of NCM and its mutants

NCMs, including non-mutated NCM and three mutants, NCM(TA), NCM(IV) and NCM(TAIV) (Fig. 1A), were composed of NHR, CHR and MPER region derived from gp41 of a clade B strain HXB2. NCMs were expressed in E. coli and purified by HPLC with C4 preparative column. Purified NCMs appeared as a single band on SDS-PAGE at ~12 kD (Fig. 1D). Chemical cross-linking of NCM with increasing concentration of glutaraldehyde (GA) resulted in the appearance of two new bands at ~24 kD (dimer) and ~36 kD (trimer) (Fig. 1E). NCMs were further characterized by ELISA using two MPER-specific neutralizing mAbs (2F5 and 4E10) [5,7,9,13,14] and a 6HB-specific mAb (NC-1) [22]. Similar to the NCM with wild-type sequence, we found that all the mutated NCMs could react with both MPER- and 6HB-specific mAbs in a dose-dependent manner (Fig. 2). These results suggest that each of these NCMs presents in solution mostly as a trimer of heterodimer (i.e., 6HBs) with three exposed MPER tails (Fig. 1C).

NCM variant with double mutations, NCM(TAIV), elicited higher titers of MPER-specific antibody responses in rabbits than NCM and its variants with single mutation, NCM(TA) and NCM(IV)

To compare the immunogenicity of the four NCMs, which show one or two amino acid difference, the rabbit antisera induced by NCMs were evaluated by testing their binding to two MPER-peptides (Table 1). Although all rabbits generated high titers of antibodies against NCMs, the immunogenicity of MPER in different NCMs varied tremendously. The antisera induced by NCM(TAIV) showed much higher titers of MPER-specific antibodies (1:12800–1:25600) than non-mutated and two other single-mutated forms (Table 1 and Fig. 3), which indicated that, among the four NCMs, NCM(TAIV) produced the best induction of MPER-specific antibodies.

MPER-specific antibodies purified from anti-NCM(TAIV) sera exhibited broad neutralizing activity

To evaluate the anti-viral activity, all antisera were tested in a pseudovirus assay using Ghost cells which express CD4, CCR5 and CXCR4. First, a sensitive pseudovirus assay to detect neutralizing antibodies (NAbs) was performed [26,30]. The antisera to NCM(TAIV) could neutralize 50% of pseudovirus expressing HXB2 or JRFL envelope proteins at a dilution of 1:20. On the other hand, no antisera exhibited 50% neutralization in a TZM-bl assay using HIV-1 isolate Bal or a p24 assay using isolate IIIB at the same dilution. The purified MPER-specific antibodies (anti-MPER) showed significant neutralizing activity to HXB2 and JRFL in a pseudovirus assay, as well as in an Env-mediated syncytium-formation, with IC₅₀ values all below 25 μg/ml (Table 2). When tested in assays using PBMC-derived viruses, MPER-specific antibodies could neutralize isolates IIIB and Bal, and several primary isolates, including 92US657 (subtype B), 93MW959 (subtype C) and 92TH009 (subtype A/E), with IC₅₀ values below 150 μg/ml, but failed to neutralize primary isolates 94UG103 (subtype A) and RU570 (subtype G) (Table 2). In contrast, no significant neutralizing activity was shown by the 6HB-specific antibodies (anti-6HB) in any of the assays. Since cell-to-cell spread of HIV-1 plays an important role in HIV-1 dissemination [31], an assay was performed to determine whether MPER-specific antibodies could inhibit cell-to-cell transmission of HIV-1. In this assay, PBMCs infected by HIV-1 IIIB or Bal were co-cultured with CEMx174 5.25M7 cells in the presence or absence of MPER-specific antibodies. As shown in Fig. 4, MPER-specific antibodies, but not 6HB-specific antibodies, blocked cell-to-cell transmission of HIV-1 IIIB and Bal strains with IC₅₀ of 56.4±7.2 and 79.2±8.1 μg/ml, respectively, suggesting that the MPER-specific antibodies are effective in blocking cell-to-cell transmission of HIV-1.

Potential mechanism to explain improved immunogenicity of NCM(TAIV)

To understand why NCM(TAIV) exhibited higher immunogenicity than NCM, NCM(TA) and NCM(IV), we used an
immunoinformatic method to predict the continuous B-cell epitopes on MPER based on recurrent neural network [32]. The results indicated that two epitopes existed in the MPER of gp41, including ELDKWASLWN and SLWNWFNITN, with scores of 0.69 and 0.50, respectively. These two epitopes actually overlap the epitopes for the human broad neutralizing mAbs 2F5 (ELDKWA) and 4E10 (NWFNIT), respectively [5,7,9,13,14]. Interestingly, the mutated epitope SLWNWFNVTN (I675V) exhibited a higher score (0.54) than the non-mutated epitope, suggesting that this sequence has a higher probability of functioning as an antibody epitope by this mutation. Subsequently, we analyzed the physicochemical property changes caused by mutation I675V with BcePred server [33]. As expected, the I675V mutation could increase the antigenic propensity of the NWFNITNW region because of the elevated hydrophilicity, flexibility and turns (Fig. 5). We could not predict the potential influence of T569A mutation on the immunogenicity of NCM(TAIV) using these methods because this residue is far away from the epitopes in the MPER of gp41.

To further define the binding site(s) of the NCM(TAIV)-induced antibodies with neutralizing activity, we synthesized 5 peptides, including MPER and M3 (which contain both 2F5 and 4E10 epitopes), M2 and M4 (containing 2F5 and 4E10 epitopes, respectively), and M1 (containing neither 2F5 nor 4E10 epitope) (Fig. 6), and used these peptides to determine the binding specificity of the purified MPER-specific antibodies with ELISA. As shown in Fig. 6, mAb 2F5 bound to MPER, M2 and M3 peptides, while mAb 4E10 recognized MPER, M3 and M4 peptides that contain the NWFNIT epitope, but showed only marginal binding activity to M2 peptide containing the ELDKWA epitope. These data indicate that the immunogen NCM(TAIV) has increased immunogenicity to induce antibodies against the 4E10 epitope.

Surface plasmon resonance (SPR) assay was utilized to evaluate the kinetics and affinity of mAbs binding to NCMs immobilized on membranes since membrane was suggested to be a crucial component of 2F5 and 4E10 epitopes. As shown in Fig. 7, there was no significant difference in kinetics and affinities of 2F5 and 4E10 for binding to NCMs immobilized on membranes since membrane was suggested to be a crucial component of 2F5 and 4E10 epitopes. As shown in Fig. 7, there was no significant difference in kinetics and affinities of 2F5 and 4E10 for binding to NCM(TAIV). Interestingly, however, the capacity of NCM(TAIV) captured into
the membranes was significantly lower than that of NCM and its analogs with single mutation (Fig. 8), thus possibly explaining why NCM(TAIV) has higher immunogenicity than NCM and other NCM mutants.

**Discussion**

We and others have made extensive efforts and used different strategies to induce neutralizing antibodies in vaccinated animals using MPER-containing peptides, recombinant proteins or surface antigen of human hepatitis B virus (HBV). Thus far, however, no one has been able to elicit potent and broad neutralizing antibodies, like 2F5 or 4E10, targeting the gp41 MPER region [34,35,36,37,38,39,40,41,42]. This can be explained by the failure of neutralizing epitopes in the MPER-based immunogens to maintain the correct conformation. It is also possible that the gp41 NHR and CHR structures at the upstream of MEPR affect the conformation and immunogenicity of neutralizing epitopes in MPER. It follows that the immunogen should contain both MPER and other regions in the gp41 ectodomain with appropriate conformation.

In the present study, we used the gp41 ectodomain as the basic structure to design the MPER-based immunogens. First, we removed the fusion peptide (FP) from the immunogen since our previous studies have shown that FP suppressed the immunogenicity of MPER and that deleting FP resulted in enhanced antigenicity and immunogenicity of the 4E10 epitope [42]. Second, we replaced the immunodominant loop region with an 8-mer (GGGKLGGG) linker, since the loop region mainly elicits cluster I antibodies [43], which do not neutralize, but rather enhance, HIV-1 infection [44]. The resulting immunogen, contains the gp41 NHR, CHR and MPER domains, thus designated NCM. Based on the crystal structure of HR1-54Q, a similarly designed recombinant gp41 containing MPER [45,46], NCM may also form 6HB core with an exposed MPER tail since it reacted strongly with the 6HB-specific mAb NC-1 [22] and the MPER-specific antibodies 2F5 and 4E10 [5,7,9,13,14] (Fig. 2). Finally, we introduced the T579A and/or I675V mutations into NCM to generate three NCM mutants, NCM(TA), NCM(IV) and NCM(TAIV) (Fig. 1A). It was reported that introduction of T659A/I675V mutations into gp41 of a neutralization-resistant HIV-1 variant significantly increased exposure of the conserved neutralization epitopes in MPER and resulted in 3- to 360-fold enhanced neutralization by 2F5 and 4E10 [19]. Therefore, we assumed that introduction of the T659A and/or I675V mutations into NCM might increase its immunogenicity for eliciting neutralizing antibodies.

Indeed, as expected, all antisera from the rabbits immunized with NCM(TAIV) had much higher titers of antibodies against the gp41 MPER domain (1:16,127) than those from rabbits vaccinated with NCM (1:504), NCM(TA) (1:1008) or NCM(IV) (1:1008) (Table 1 and Fig. 3), suggesting that introducing both mutations (T659A/I675V) could significantly enhance the immunogenicity of the NCM-based immunogen.

There are two major antibody populations in the rabbit antisera induced by NCM(TAIV) – the 6HB-specific and MPER-specific antibodies. We purified these antibodies using affinity columns conjugated with a recombinant 6HB protein and an MPER peptide, respectively, and compared their neutralizing activities. The 6HB-specific antibodies had no neutralizing activity at the concentration of >150 µg/ml, while the MPER-specific antibodies exhibited inhibitory activity against HIV-1 Env-mediated syncytium-formation and infection by HIV-1 pseudoviruses, laboratory-adapted and some primary HIV-1 isolates (Table 2). These results indicate that the altered epitopes in the gp41 MPER, rather than those in the gp41 6HB core, elicit neutralizing antibodies in vaccinated animals.

The precise mechanism by which these mutations exposed neutralization epitopes remained unclear, since chemical cross-linking assay, together with antibodies binding assays by ELISA and SPR, indicated no significant difference between NCM and mutants. However, several studies have demonstrated that strictly conserved T569 and I675 residues play important roles in viral entry. T569 residue is located in the inner face of NHR trimer and falls within the hydrophobic pocket which is critical for interaction with CHR. Therefore, T569A mutation may partially disrupt the gp41 6HB core conformation [19], resulting in change of the overall conformation of gp41. It was reported that the I675V mutation could affect some physicochemical properties of MPER which contribute to increased immunogenicity. However, these changes could not fully explain the strong immunogenicity of MPER in NCM(TAIV), since single-mutated NCM(IV) did not elicit high titers of MPER-specific antibodies. Therefore, we considered the effect of another interesting finding that NCM(TAIV) showed lower capture level to membranes. Many studies reported that the membrane plays a crucial role in defining the structure of the MPER and, consequently, the formation of the 2F3 and 4E10 epitopes. The long CDR-H3s of these antibodies were involved in the

---

**Figure 8. Capture levels of NCMs binding to membrane.** (A) Sensorgrams obtained for 1 µM NCMs binding to POPC/Chol/SM membranes on the L1 sensor chips. (B) Different capture levels of NCMs (RUs at 400s post-injection).

doi:10.1371/journal.pone.0018233.g008
interaction with lipids [47,48]. However, the immersion of MPER in membrane may have a negative effect on immunogenicity of MPER because of the steric restrictions imposed by the viral membrane which may hamper the generation of antibodies. Although the rabbits were immunized with NCM and mutants in the absence of liposomes, the immunogen could diffuse and nonspecifically interact with membrane systems in multiple immune processes after subcutaneous injections. This interaction may result in the decreased exposure of the epitopes on MPER, rendering a correspondingly poorer immunogenicity. On the contrary, decreasing the immersion depth of epitopes in membranes, which made MPER more exposed, but antigenically preserved, was another reason underlying the ability of NCM(TAIV) to elicit higher titers of MPER-specific antibodies. Interestingly, the induced MPER-specific antibodies mainly targeted an extended 4E10 epitope as we had expected. Thus, physicochemical property and structure changes, together with decreased immersion depth, may correlate with the increased immunogenicity of MPER in NCM(TAIV).

Although NCM(TAIV) could elicit relatively higher titers of MPER-specific antibodies than non-mutated NCM or other gp41-derived recombinant proteins described previously, it lacks the ability to induce highly potent and broad neutralizing antibodies against primary HIV-1 isolates. Therefore, more efforts should be taken to make NCM(TAIV) a rational candidate for an HIV vaccine to elicit higher tier and more potent and broader neutralizing antibodies. Fortunately, many studies have provided some useful suggestions, such as implementing a new immunization strategy [15], using strong adjuvants to break B-cell tolerance [50], or introducing mutations which could favor the formation of prehairpin intermediate conformation or prolong exposure of MPER [31,32].

In conclusion, our study presented a rationally designed immunogen consisting of the gp41 6HB core and the exposed MPER tail with a double mutation (T569A and I675V). This immunogen could elicit high titers of MPER-specific antibodies with broad neutralizing activity. Although the precise underlying molecular mechanism remained unclear, we confirmed that that double T569A/I675V mutations in gp41 are critical for significantly enhancing the immunogenicity of neutralizing epitopes in the gp41 MPER. Therefore, this study might provide important implications for designing novel MPER-based HIV-1 vaccines with increased immunogenicity for eliciting potent and broad neutralizing antibodies.

Acknowledgments
We thank Dr. Linqi Zhang for providing Ghost cell line.

Author Contributions
Conceived and designed the experiments: YHC SJ. Performed the experiments: JW PT LL LZ LX. Analyzed the data: JW YHC SJ. Wrote the paper: JW YHC SJ.

References
1. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nature Reviews Immunology 4: 199-210.
2. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J, et al. (2007) Antibody-based HIV-1 vaccines: Recent developments and future directions. PLoS Medicine 4: 1067-1071.
3. Li YX, Miguesa SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Medicine 13: 1032-1034.
4. Gray ES, Madiga MC, Moore PL, Klima A, Svehla K, et al. (2007) Broad HIV-1 neutralization mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 83: 11265-11274.
5. Muster T, Seindl F, Parusch M, Trikola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp120 of human immunodeficiency virus type 1. J Virol 67: 6643-6647.
6. Zwick MB, Labrein AF, Wang M, Spelenhauer C, Saraph EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10989-10993.
7. Olek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp120 epitope. J Virol 78: 10724-10737.
8. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252-1261.
9. Cardoso RMF, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
10. Sun ZY, Oh KJ, Kin M, Yu J, Brusic V, et al. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp120 ectodomain region on the viral membrane. Immunity 28: 52-63.
11. Walker LM, Phogat SK, Chua-Hui PY, Wapper D, Phung P, et al. (2009) Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science 326: 285–289.
12. Wu X, Yang ZY, Li Y, Hogerkoop CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
13. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
14. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcclar B, et al. (2004) Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 78: 14039-14042.
15. Montero M, van Houten NF, Wang X, Scott JK (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design (vol 72, pg 54, 2008). Microbiology and Molecular Biology Reviews 72: 378-379.
16. Zhang MY, Wang Y, Mankowski MK, Pak RG, Dimitrov DS (2009) Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen. Vaccine 27: 857–863.
17. Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL (2007) Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 25: 5102-5114.
18. Law M, Cardoso RM, Wilson IA, Burton DR (2007) Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 81: 4272-4285.
19. Blish CA, Nguyen MA, Overbaugh J (2008) Enhancing exposure of HIV-1 neutralizing epitopes through mutations in gp41. PLoS Med 5: e9.
20. Huang JH, Qi Z, Wu F, Kotula L, Jiang S, et al. (2008) Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV. J Biol Chem 283: 14994–15002.
21. Mische CG, Yuan W, Strick B, Craig S, Farzam M, et al. (2005) An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor. Virology 338: 133–143.
HIV-1 MPER & Core Induce Neutralizing Antibody

22. Jiang S, Lin K, Lu M (1998) A conformation-specific monoclonal antibody reacting with fusion-active gp120 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 72: 10213–10217.

23. Vegi AS, Pattenden LK, Fletcher JM, Castano M, Aguilar MI (2009) Interactions of HIV-1 Antibodies 2F5 and 4E10 with a gp41 Epitope Prebound to Host and Viral Membrane Model Systems. ChemBiochem 10: 1032–1044.

24. Zhu Y, Lu L, Xu L, Yang H, Jiang S, et al. (2010) Identification of a gp41 core-binding molecule with homologous sequence of human TNN1-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. J Virol 84: 9359–9368.

25. Chou TC, Talalay P (1984) Quantitative-Analysis of Dose-Effect Relationships - the Combined Effects of Multiple-Drugs or Enzyme-Inhibitors. Advances in Enzyme Regulation 22: 27–55.

26. Heyndrickx L, Vermoesen T, Vercruyssen K, Kurth J, Coppens S, et al. (2008) Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. Journal of Virological Methods 148: 166–173.

27. Neurath AR, Strick N, Jiang SB, Li YY, Dehmath AK (2002) Anti-HIV-1 activity of cellulosic acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. Bruc Infectious Diseases 2: 41.

28. Li L, He I, Tan S, Gao X, Lu H, et al. (2010) 3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother 54: 1700–1711.

29. Li L, Qiao F, Yang J, Lu L, Tan S, et al. (2010) Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology 7: 37.

30. Fenyos EM, Heath A, Diopnseri S, Holmes H, Lusso P, et al. (2009) International Network for Comparison of HIV Neutralization Assays: The NeuNet Report. PLoS ONE 4: e4505.

31. Santattau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815–826.

32. Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Artificial Immune Systems, Proceedings 3239: 197–204.

33. Erkhart I, Raffelsberger W, Ferko B, Klima A, Purtscher M, et al. (1996) Identification of a gp41 core-binding molecule with homologous sequence of human TNN1-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. J Virol 84: 9359–9368.

34. Coefiier E, Clement JM, Cassac V, Khodaei-Bozrane N, Jehanno M, et al. (2000) Antigenicity and immunogenicity of the HIV-1 gp120 epitope ELDKWA inserted into permissive sites of the MalF protein. Vaccine 19: 684–693.

35. Tian H, Xiao Y, Zhu M, Chen YH (2001) HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies. Int Immunopharmacol 1: 763–768.

36. Li H, Liu ZQ, Ding J, Chen YH (2002) Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1. Immunol Lett 84: 153–157.

37. Ho J, MacDonald KS, Barber BH (2002) Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 20: 1169–1180.

38. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, et al. (2002) Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP176 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 277: 45011–45020.

39. Wang Z, Liu Z, Cheng X, Chen YH (2003) The recombinant immunogen with high-density epitopes of ELDKWA and ELDAWA induced antibodies recognizing both epitopes on HIV-1 gp41. Microbiol Immunol 49: 703–709.

40. Li J, Chen X, Jiang S, Chen YH (2008) Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. Biochem Biophys Res Commun 376: 60–64.

41. Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Artificial Immune Systems, Proceedings 3239: 197–204.

42. Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Artificial Immune Systems, Proceedings 3239: 197–204.

43. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, et al. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 6: e1000880.

44. Scherer EM, Leaman DP, Zoeck MB, McMichael AJ, Burton DR (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107: 1529–1534.

45. Dennison SM, Stewart SM, Stampel KC, Liao HX, Haynes BF, et al. (2009) Stable Docking of Neutralizing HIV-1 Gp41 Membrane Proximal External Region Monoclonal Antibodies 2F5 and 4e10 Is Dependent on the Membrane Immersion Depth of Their Epitope Regions. J Virol 83: 10211–10223.

46. Haynes BF, Moody MA, Verkoczy L, Kolvo G, Alain SM (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 14: 59–67.

47. O’Rourke SM, Schweighardt B, Scott WG, Winr T, Fonsce DA, et al. (2009) Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies. J Virol 83: 7278–7288.